RxDoctor Payments Data

Calvin Ledford, MD

Interventional Cardiology · Chattanooga, TNNPI 1033180971

Payments from drug & device makers

$2,757in general payments, 2019–2025

Across 74 payments — averaging $37.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$915
  • Abbott$551
  • Medtronic$343
  • Abiomed$239
  • Novartis$215
  • Heartflow, Inc.$165
  • plus $329 from 7 others

What the payments were for

  • Travel & lodging$91533%
  • Food & beverage$1,84267%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medical Device Business Services, Inc.4$915
Abbott18$551
Medtronic(2 entities)29$343
Abiomed3$239
Novartis9$215
Heartflow, Inc.1$165
Getinge USA Sales, LLC2$139
Celonova Biosciences, Inc.1$80
Pfizer2$32
Philips North America LLC2$31
Novo Nordisk1$19
Cordis US CORP.1$15
Amgen1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,757 in reported general payments places this provider in the 15th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$228,863
Medicare patients
1,630
Services billed
3,670

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban786$886,762
EntrestoSacubitril/Valsartan303$344,860
XareltoRivaroxaban184$213,757
Repatha SureclickEvolocumab168$160,363
JardianceEmpagliflozin96$107,176
Ranolazine ErRanolazine85$17,354
Dabigatran EtexilateDabigatran Etexilate Mesylate59$17,062
FarxigaDapagliflozin Propanediol13$13,669
VascepaIcosapent Ethyl20$12,163
BrilintaTicagrelor16$10,148
Atorvastatin Calcium732$9,867
Metoprolol Succinate596$8,754
Prasugrel Hcl69$7,162
Flecainide Acetate158$7,119
Valsartan147$6,965

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$886,762786 claims
NovartisEntresto$215$344,860303 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →